Myovant Sciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) announced participation in investor conferences, including the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, and the Cowen 42nd Annual Health Care Conference on March 8, 2022. CEO David Marek and the executive team will engage in a fireside chat, with webcasts available to the public on the Myovant website. The company aims to redefine care for women and men through innovative treatments, having achieved two FDA approvals and additional regulatory submissions currently under review.

BASEL, Switzerland, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and other members of the Myovant executive team will participate in a fireside chat at the following investor conferences:

• 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:00 p.m. Eastern Time.
  
  
• Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022, at 9:50 a.m. Eastern Time.
  

Investors and the general public are invited to listen to the webcasts, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across oncology and women’s health leading to two regulatory approvals by the U.S. Food and Drug Administration for men with advanced prostate cancer and women with heavy menstrual bleeding associated with uterine fibroids, respectively, as well as regulatory approvals by the European Commission and the Medicines and Healthcare products Regulatory Agency for women with symptomatic uterine fibroids. Additionally, Myovant has two regulatory submissions under review, a Marketing Authorization Application in advanced prostate cancer and a supplemental New Drug Application in endometriosis-associated pain. Myovant is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. Myovant is also developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao
Director, Corporate Communications
+1 (650) 410-3055
media@myovant.com

FAQ

What conferences is Myovant Sciences participating in February and March 2022?

Myovant Sciences will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, and the Cowen 42nd Annual Health Care Conference on March 8, 2022.

Who will represent Myovant Sciences at the investor conferences?

David Marek, the CEO of Myovant Sciences, along with other members of the executive team, will represent the company at the conferences.

How can I listen to Myovant Sciences' fireside chat during the conferences?

Investors and the public can listen to the webcasts of Myovant Sciences' fireside chat on the Events page of their website.

What are Myovant Sciences' recent achievements in drug approvals?

Myovant Sciences has received two FDA approvals, one for advanced prostate cancer and one for women with heavy menstrual bleeding associated with uterine fibroids.

What is the focus of Myovant Sciences as a healthcare company?

Myovant Sciences focuses on redefining care for women and men through innovative treatments and transformative advocacy.